
	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands except per share amounts)	2025		2024		2025		2024
Numerator:
Net income	$	10,879	$	994	$	19,147	$	6,187
Less: Dividends and accretion attributable to redeemable senior preferred stockholders	—		(18,565)		—		(31,227)
Less: Return on redeemable NCI	—		(58)		—		(639)
Net income (loss) attributable to common stockholders	$	10,879	$	(17,629)	$	19,147	$	(25,679)

Weighted average shares outstanding(1)	78,981		77,736		78,878		77,878
Effect of dilutive potential common shares	856		—		1,090		—
Adjusted Weighted average shares outstanding	79,837		77,736		79,968		77,878

Basic Earnings (loss) per common share	$	0.14	$	(0.23)	$	0.24	$	(0.33)
Diluted Earnings (loss) per share	$	0.14	$	(0.23)	$	0.24	$	(0.33)

(1)For the three and six months ended June 30, 2024, the weighted-average common shares outstanding includes 1,803,841 warrants. These shares of common stock had an exercise price of $0.001 and were exercised on January 14, 2025. The warrants are considered to be equity contracts indexed in the Company's own shares and therefore were recorded at their inception date relative fair value and are included in additional paid-in capital on the Company's Unaudited Consolidated Balance Sheets.

For the three and six months ended June 30, 2025, the Company had 0.9 million and 1.1 million, respectively, dilutive securities that were included in the Company's diluted earnings per share. For the three and six months ended June 30, 2024, all potentially dilutive securities were anti-dilutive, so diluted net loss per share was equivalent to basic net loss per share. Anti-dilutive securities that were excluded from the Company's earnings (loss) per common share are as follows:


	Three Months Ended June 30,		Six Months Ended June 30,
(in thousands)	2025	2024	2025	2024


Restricted stock awards(1)	26	889	—	946
Liability-classified restricted stock units	—	—	—	—
Outstanding stock option awards(1)	—	866	—	865
Total	26	1,755	—	1,811